Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Wharf Rat who wrote (1331307)	12/1/2021 12:49:59 PM
From: Broken_Clock	Read Replies (1) \| Respond to of 1572629

“exploiting the tragedy of people who became victims of criminal pseudo-medical experiments in Auschwitz in a debate about vaccines, pandemic and people who fight for saving human lives is shameful.” If that were the case, but it isn't. First point, big pharma isn't "fighting to save human lives" BP is fighting to make money and they don't care how they do it, even if it means destroying lives by experimenting on a the entire world's population. Note that Bourla's "beliefs" are now scientifically proven to be incorrect. Jerusalem Post Health & Wellness Pfizer CEO Albert Bourla calls Israel 'world's lab' in interview to NBC Bourla further noted that studies on the risk of the vaccine are also underway on pregnant women and younger children. By CODY LEVINE Published: FEBRUARY 27, 2021 15:15 Updated: MARCH 9, 2021 17:15 "I believe Israel has become the world's lab right now because they are using only our vaccine at this state and they have vaccinated a very big part of their population, so we can study both economy and health indices," said Pfizer CEO Albert Bourla during an interview given to NBC News on Friday. "What we've seen is that the vaccine efficacy in real-world data is getting higher as we speak, following the second vaccination, so seven days compared to 14 days post-second vaccination, there is a difference in efficacy," Bourla claimed. When asked whether one could infect others after receiving two doses of the vaccine, he said: "It is something that needs to be confirmed, and the real-world data that we are getting from Israel and other studies will help us understand this better. "But there are a lot of indicators right now that are telling us that there is a protection against the transmission of the disease," Bourla added. Bourla further noted that studies on the risk of the vaccine are also underway on pregnant women and younger children. "We have already licensed for kids 16 and above... we are already doing trials for kids between 11 years old all the way to 16, and I hope that we will be able to have data in a couple of months. We are also planning to initiate pediatric studies from a younger age, from age 5 all the way to 11. And I believe we should have data about this population by the end of the year," Bourla said, according to NBC. Regarding how long the protection remains after receiving both doses of the vaccine, Bourla said current data shows that after six months the protection is robust, but we need to wait until a year in order to determine if it remains for the full year. The NBC interview also made mention of the recent Israeli study regarding the effectiveness of the vaccine, with Bourla noting that the data came largely from a younger population. He said it remains a high risk to rely on only one dose of the vaccine to combat the coronavirus.